+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Investigation Report on China's Recombinant Human Endostatin Market, 2019-2023

  • ID: 4828468
  • Report
  • August 2019
  • Region: China
  • 30 Pages
  • China Research & Intelligence
1 of 5
The Sales Value of Recombinant Human Endostatin Grew to CNY 272 Million in 2017, with a CAGR of 16.47%

FEATURED COMPANIES

  • Yantai Medgenn Co., Ltd.
  • MORE

In 2008, lung cancer replaced liver cancer to be the malignant tumor with the highest fatality rate in China. Over the past 30 years, lung cancer has become a heavy burden on the Chinese people and society.
In 2017, the number of lung cancer patients in China rose to 800,000; 700,000 people died of lung cancer, accounting for over 20% of the cancer deaths in China. The incidence of lung cancer is growing at an annual rate of more than 20%. It is expected that in 2025, lung cancer will kill nearly 1 million people in China. In 2017, the number of lung cancer patients in China and the number of people who died of lung cancer in China both accounted for 40% of the global total. And about 80% of the lung cancer patients had non-small cell lung cancer (NSCLC).

Recombinant Human Endostatin, an angiogenesis inhibitor, was developed by a Chinese enterprise in 1999 and approved by the China Food and Drug Administration (CFDA) in 2005 to be used in the combination chemotherapy for the recurrence and metastasis of NSCLC. Recombinant Human Endostatin acts on vascular endothelial cells to inhibit the movement of endothelial cells that form blood vessels and the formation of tumor angiogenesis and block the nutrition supply to tumor cells. In this way, it inhibits tumor proliferation or metastasis.

The sales value of Recombinant Human Endostatin increased sharply after it was launched in China. It rose from CNY 148 million in 2013 to CNY 272 million in 2017, representing a CAGR of 16.47%.

By Aug. 2019, only one enterprise’s Recombinant Human Endostatin has been approved to be sold in China. In the context of worsening environmental pollution and over 300 million smokers, the number of lung cancer patients in China will continue to increase in the next few years. Therefore, the market size of Recombinant Human Endostatin will keep expanding and more enterprises will launch their Recombinant Human Endostatin products in China.

Topics covered:

  • Incidence of lung cancer in China
  • Status of China's Recombinant Human Endostatin market
  • Prices of Recombinant Human Endostatin in China
  • Development trends of Recombinant Human Endostatin in China
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Yantai Medgenn Co., Ltd.
  • MORE

1 Relevant Concepts of Recombinant Human Endostatin
1.1 Indications for Recombinant Human Endostatin
1.2 Development of Recombinant Human Endostatin in China
1.3 Patents and Government Approval on Recombinant Human Endostatin in China

2 Sales of Recombinant Human Endostatin in China, 2013-2017
2.1 Sales Value
2.2 Sales volume
2.3 Sales of Recombinant Human Endostatin by Dosage Form in China, 2013-2017

3 Analysis of Major Manufacturers of Recombinant Human Endostatin in China, 2013-2017
3.1 Analysis on Market Share of Major Manufacturers of Recombinant Human Endostatin
3.2 Yantai Medgenn Co., Ltd.

4 Prices of Recombinant Human Endostatin in China, 2017-2018
4.1 Yantai Medgenn Co., Ltd. (Endostar)
4.2 Analysis of Potential Competitors

5 Prospect of China's Recombinant Human Endostatin Market, 2019-2023
5.1 Factors Influencing Development of China's Recombinant Human Endostatin Market
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Charts

Chart: Sales of Recombinant Human Endostatin in China, 2013-2017
Chart: Sales Value of Recombinant Human Endostatin in Parts of China, 2013-2017
Chart: Sales Volume of Recombinant Human Endostatin in China, 2013-2017
Chart: Sales Volume of Recombinant Human Endostatin in Parts of China, 2013-2017
Chart: Sales Value of Recombinant Human Endostatin Injection in China, 2013-2017
Chart: Sales Volume of Recombinant Human Endostatin Injection in China, 2013-2017
Chart: Sales Value of Recombinant Human Endostatin by Yantai Medgenn Co., Ltd., 2013-2017
Chart: Prices of Recombinant Human Endostatin by Yantai Medgenn Co., Ltd. in Parts of China, 2017-2018
Chart: Patents on Recombinant Human Endostatin in China
Chart: Government Approval on Recombinant Human Endostatin in China
Chart: Forecast on Sales Value of Recombinant Human Endostatin in China, 2019-2023

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Yantai Medgenn Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...

Adroll
adroll